These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Prolonged oral etoposide therapy in advanced stage lung cancer].
    Author: Bozóky G, Ruby E, Góhér I, Mohos A, Lengyel M.
    Journal: Orv Hetil; 1997 Jul 13; 138(28):1791-5. PubMed ID: 9280873.
    Abstract:
    Authors discuss results of the prolonged oral etoposide treatment of 79 patients with advanced stage lung cancer. Thirty patients with small-cell lung cancer were treated with Cisplatin in combination with prolonged oral etoposide. Response rate was nearly 100%. Most of the patients (24) were in partial remission, and the mean survival time was 15 months. Forty-nine patients with non-small cell lung cancer were divided at random into two groups: patients in the first group (n = 25) were treated with Cisplatin in combination with prolonged oral etoposide. In the second group (n = 24) was used only prolonged oral etoposide therapy for 14-, or 21 days. Encouraging response rate have been observed with long-term daily administration of oral etoposide to treat non-small cell lung cancer. In both groups there was a response rate nearly 80%. Most of the patients in these two subgroups got into partial remission, and a rest were in stable clinical stage (median duration was 5 months). Besides alopecia, which occurred in all patients, myelosuppression (agranulocytosis) was the predominate toxicity (agranulocytosis in 5 cases), which was affectively treated with combined supportive care. Etoposide given by this dose and schedule (100 mg/d for 14 days) has activity as first-line systemic therapy in combination with Cisplatin for advanced small-cell lung cancer and, has a moderate activity for treatment of non-small cell lung cancer.
    [Abstract] [Full Text] [Related] [New Search]